Specific PET Imaging Probes for Early Detection of Prostate Cancer Metastases

2012 ◽  
Author(s):  
Xiankai Sun
Keyword(s):  
Prostate Cancer ◽  
Early Detection ◽  
Pet Imaging ◽  
Cancer Metastases ◽  
Imaging Probes

Tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 25-25 ◽  
Author(s):  
Michael J. Morris ◽  
Neeta Pandit-Taskar ◽  
Scott T. Tagawa ◽  
David M. Nanus ◽  
Stephen Barnett Solomon ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pet Imaging ◽  
Fdg Pet ◽  
Imaging Modality ◽  
Bone Lesions ◽  
Castration Resistant Prostate Cancer ◽  
Cancer Metastases ◽  
External Domain ◽  
Tumor Distribution ◽  
Bone Scans

25 Background: There is no standard imaging modality that specifically and accurately images prostate cancer metastases, hampering assessments of tumor distribution, prognostication, and response. J591 is a humanized antibody that targets the external domain of PSMA, which is copiously expressed in metastatic disease and upregulated in mCRPC. We have previously reported on the feasibility, and PK and biodistribution properties of Zr-89-J591 in 10 patients (Morris et al, GU ASCO 2013). We now report on the targeting/accuracy in 49 patients with mCRPC. Methods: Following standard CT/MRI, bone scintigraphy, and FDG PET imaging, 5 mCi of Zr-89-J591 was administered intravenously. Zr-89-J591 was imaged 6-8 days after injection. Positive scan findings were confirmed, where possible, with biopsies in the following preference: Zr-89-J591 and FDG positivity, then Zr-89-J591 and FDG mismatch, and lastly standard imaging and any PET mismatch. Results: A total of 535 unique bone lesions in 49 patients were identified using all imaging modalities. 339 (63%) of these were evident on bone scans, 302 (56%) on CT, 202 (38%) on FDG PET, and 490 (92%) on Zr-89-J591 PET. The concordance between bone scans and Zr-89-J591 was 303/490 (62%). 102 sites were seen only on Zr-89-J591 and not on any other imaging modality. 44 biopsies were performed from 33 patients; 21 of those biopsies were bone. The histopathologic correlation for bone is provided in the table below. All positive biopsies were J591 positive (16/16); sensitivity of J591 was =100%, and positive predictive value (16/18) was 89%. Conclusions: Imaging using J591 PET/CT detects bone disease at greater rates than any other imaging modality tested. Biopsy data of J591 positive lesions suggest that most J591 positive lesions represent biopsy confirmed prostate metastasis. We are now testing minibodies based on J591 that may target faster, offering a more favorable imaging schedule. Clinical trial information: NCT01543659. [Table: see text]

The Role of 11C-Choline PET Imaging in the Early Detection of Recurrence in Surgically Treated Prostate Cancer Patients With Very Low PSA Level <0.5 ng/mL

2013 ◽  
Vol 38 (9) ◽  
pp. e342-e345 ◽  
Author(s):  
Marcelo Mamede ◽  
Francesco Ceci ◽  
Paolo Castellucci ◽  
Riccardo Schiavina ◽  
Chiara Fuccio ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Early Detection ◽  
Cancer Patients ◽  
Pet Imaging ◽  
Choline Pet

1820: Complexed PSA for Early Detection of Prostate Cancer: A Multi Institutional Study

2004 ◽  
Vol 171 (4S) ◽  
pp. 481-481
Author(s):  
Ravery V. Vincent ◽  
Chautard D. Denis ◽  
Arnauld A. Villers ◽  
Laurent Boccon Gibbod
Keyword(s):  
Prostate Cancer ◽  
Early Detection
Sign in / Sign up

Export Citation Format

Share Document